Context Therapeutics (CNTX) director awarded 45,000 stock options at $0.576

Rhea-AI Filing Summary

Context Therapeutics Inc. director Luke Nathaniel Walker received a grant of 45,000 stock options to buy Common Stock at an exercise price of $0.576 per share. The options vest on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders and expire on June 23, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Walker Luke Nathaniel

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	45,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 45,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 45,000 options Exercise price: $0.576 per share Total derivative holdings after grant: 45,000 options +2 more

5 metrics

Options granted 45,000 options Stock Option (right to buy) granted to director

Exercise price $0.576 per share Conversion or exercise price for Common Stock

Total derivative holdings after grant 45,000 options Total stock options following this transaction

Vesting date Earlier of June 24, 2027 or 2027 annual meeting Vesting condition subject to continued service

Expiration date June 23, 2036 Option term end date if unexercised

Key Terms

Stock Option (right to buy), exercise price, expiration date, annual meeting of stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 0.5760"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-23T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"the Issuer's 2027 annual meeting of stockholders, subject to continued service"

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 04:21 PM Accepted by SEC EDGAR 06/26/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walker Luke Nathaniel

(Last) (First) (Middle)

2001 MARKET STREET

SUITE 3915 UNIT #15

(Street)

PHILADELPHIA PENNSYLVANIA 19103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Context Therapeutics Inc. [ CNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.576	06/24/2026		A		45,000		(1)	06/23/2036	Common Stock	45,000	$0	45,000	D

Explanation of Responses:

1. The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.

Remarks:

	/s/ Alex Levit, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Context Therapeutics (CNTX) report for Luke Nathaniel Walker?

Context Therapeutics reported a stock option grant to director Luke Nathaniel Walker. He received 45,000 options to buy Common Stock as a compensation award, recorded on a Form 4 insider filing, rather than an open-market stock purchase or sale.

How many Context Therapeutics (CNTX) stock options were granted to the director?

Luke Nathaniel Walker was granted 45,000 stock options. These options give him the right to buy 45,000 shares of Context Therapeutics Common Stock, subject to vesting conditions and a fixed exercise price disclosed in the Form 4 filing.

What is the exercise price and expiration date of the new CNTX stock options?

The granted options have an exercise price of $0.576 per share. They allow the director to buy Context Therapeutics Common Stock at this price and will expire on June 23, 2036 if not exercised before that date.

When do Luke Nathaniel Walker’s Context Therapeutics (CNTX) options vest?

The options vest on the earlier of June 24, 2027 or the 2027 annual meeting. Vesting is also conditioned on his continued service with Context Therapeutics, according to the footnote in the Form 4 filing.

Is the CNTX Form 4 transaction an open-market stock purchase or a compensation grant?

The CNTX Form 4 reflects a compensation-related stock option grant, not an open-market trade. The transaction code “A” and description indicate a grant or award acquisition at a set exercise price, with zero cash paid at grant.